Interleukin-10 polymorphism in position-1082 and acute respiratory distress syndrome

European Respiratory Journal

Volumn 27, Issue 4, 2006, Pages 674-681

  Gong, M N ^a   Thompson, B T ^b   Williams, P L ^c   Zhou, W ^c   Wang, M Z ^c   Pothier, L ^c   Christiani, D C ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Acute respiratory distress syndrome; Interleukin 10; Mortality; Polymorphism

Indexed keywords

INTERLEUKIN 10;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGE; AGED; ARTICLE; ASPIRATION PNEUMONIA; BLOOD TRANSFUSION; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RISK FACTOR; SCORING SYSTEM; SEPSIS; THORAX BLUNT TRAUMA; ADOLESCENT; CAUSE OF DEATH; GENETICS; MIDDLE AGED; PROSPECTIVE STUDY; SURVIVAL; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CAUSE OF DEATH; FEMALE; GENOTYPE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN-10; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 33747591930     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00046405     Document Type: Article

References (45)

1. Hudson LD, Milberg JA, Anardi D, Maunder RJ. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 151: 293-301.
2. Gong MN, Thompson BT, Pothier L, Boyce P, Christiani DC. Predictors for the development of and mortality in ARDS: potential role of red cell transfusion. Crit Care Med 2005; 33: 1191-1198.
3. Marshall RP, Webb S, Bellingan GJ, et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 166: 646-650.
4. Quasney MW, Waterer GW, Dahmer MK, et al. Association between surfactant protein B + 1580 polymorphism and the risk of respiratory failure in adults with community-acquired pneumonia. Crit Care Med 2004; 32: 1115-1119.
5. Garred P, Strom JJ, Quist L, Taaning E, Madsen HO. Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 2003; 188: 1394-1403.
6. Oberholzer A, Oberholzer C, Moldawer LL. Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002; 30: Suppl. 1, S58-S63.
7. Latifi SQ, O'Riordan MA, Levine AD. Interleukin-10 controls the onset of irreversible septic shock. Infect Immun 2002; 70: 4441-4446.
8. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 1996; 64: 4733-4738.
9. Steinhauser ML, Hogaboam CM, Kunkel SL, Lukacs NW, Strieter RM, Standiford TJ. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 1999; 162: 392-399.
10. Marchant A, Deviere J, Byl B, De Groote D, Vincent JL, Goldman M. Interleukin-10 production during septicaemia. Lancet 1994; 343: 707-708.
11. Neidhardt R, Keel M, Steckholzer U, et al. Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J Trauma 1997; 42: 863-870.
12. Igonin AA, Armstrong VW, Shipkova M, Lazareva NB, Kukes VG, Oellerich M. Circulating cytokines as markers of systemic inflammatory response in severe community-acquired pneumonia. Clin Biochem 2004; 37: 204-209.
13. Monneret G, Finck ME, Venet F, et al. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett 2004; 95: 193-198.
14. Simmons EM, Himmelfarb J, Sezer MT, et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 2004; 65: 1357-1365.
15. Armstrong L, Millar AB. Relative production of tumor necrosis factor-α and interleukin-10 in adult respiratory distress syndrome. Thorax 1997; 52: 442-446.
16. Parsons PE, Moss M, Vannice JL, Moore EE, Moore FA, Repine JE. Circulating IL-1ra and IL-10 levels are increased but do not predict the development of acute respiratory distress syndrome in at-risk patients. Am J Respir Crit Care Med 1997; 155: 1469-1473.
17. Donnelly SC, Strieter RM, Reid PT, et al. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Ann Intern Med 1996; 125: 191-196.
18. Westendorp RG, Langermans JA, Huizinga TW, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170-173.
19. Reuss E, Fimmers R, Kruger A, Becker C, Rittner C, Hohler T. Differential regulation of interleukin-10 production by genetic and environmental factors-a twin study. Genes Immun 2002; 3: 407-413.
20. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8.
21. Suarez A, Castro P, Alonso R, Mozo L, Gutierrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 2003; 75: 711-717.
22. Galley HF, Lowe PR, Carmichael RL, Webster NR. Genotype and interleukin-10 responses after cardiopulmonary bypass. Br J Anaesth 2003; 91: 424-426.
23. Gallagher PM, Lowe G, Fitzgerald T, et al. Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 2003; 58: 154-156.
24. Schaaf BM, Boehmke F, Esnaashari H, et al. Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Respir Crit Care Med 2003; 168: 476-480.
25. Reid CL, Perrey C, Pravica V, Hutchinson IV, Campbell IT. Genetic variation in proinflammatory and anti-inflammatory cytokine production in multiple organ dysfunction syndrome. Crit Care Med 2002; 30: 2216-2221.
26. Balding J, Healy CM, Livingstone WJ, et al. Genomic polymorphic profiles in an Irish population with meningococcaemia: is it possible to predict severity and outcome of disease? Genes Immun 2003; 4: 533-540.
27. Jaber BL, Rao M, Guo D, et al. Cytokine gene promoter polymorphisms and mortality in acute renal failure. Cytokine 2004; 25: 212-219.
28. Schroder O, Laun RA, Held B, Ekkernkamp A, Schulte KM. Association of interleukin-10 promoter polymorphism with the incidence of multiple organ dysfunction following major trauma: results of a prospective pilot study. Shock 2004; 21: 306-310.
29. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100: 1619-1636.
30. Bernard GR, Doig G, Hudson L. Quantification of organ failure for clinical trials and clinical practice. Am J Respir Crit Care Med 1995; 151: A323.
31. Jurinke C, van den Boom D, Cantor CR, et al. The use of MassARRAY technology for high throughput genotyping. Adv Biochem Eng Biotechnol 2002; 77: 57-74.
32. Hosmer DW, Lemeshow S. Assessing the fit of model. In: Applied Logistic Regression. 2nd Edn. USA, Wiley-Interscience Publication, 2000; pp. 160-164.
33. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late life disease and frailty. Annu Rev Med. 2000; 51: 245-270.
34. Marik PE, Zalonga GP, Norasept II Study Investigators. The effect of aging on circulating levels of pro-inflammatory cytokines during septic shock. J Am Geriatric Soc 2001; 49: 5-9.
35. Bruunsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am 2003; 23: 15-39.
36. Gogos CA, Drosou E. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000; 181: 176-180.
37. Goodman RB, Pugin J, Lee JS, Matthay MA. Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev 2003; 14: 523-535.
38. Zanotti S, Kumar A, Kumar A. Cytokine modulation in sepsis and septic shock. Expert Opin Investig Drugs 2002; 11: 1061-1075.
39. Montgomery AB, Stager MA, Carrico CJ, Hudson LD. Causes of mortality in patients with adult respiratory distress syndrome. Am Rev Respir Dis 1985; 132: 485-489.
40. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24: 1125-1128.
41. Park WY, Goodman RB, Steinberg KP, et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 164: 1896-1903.
42. Wacholder S, Rothman N, Caporaso N. Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 2000; 92: 1151-1158.
43. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003; 349: 2201-2210.
44. Ma SL, Tang NL, Lam LC, Chiu HF. The association between promoter polymorphism of the interleukin-10 gene and Alzheimer's disease. Neurobiol Aging 2005; 26: 1005-1010.
45. Lowe PR, Galley HF, Abdel-Fattah A, Webster NR. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 2003; 31: 34-38.